Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 06/05/20
Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Cancer Treatment DevelopmentInvestors Business Daily • 05/18/20
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell TherapyGlobeNewsWire • 05/12/20
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/20
Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings?Zacks Investment Research • 04/30/20
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia TherapeuticsGlobeNewsWire • 03/31/20
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 MilestonesGlobeNewsWire • 01/09/20
Gene-Editing Stocks Dive As Creator Of CRISPR Babies Goes To PrisonInvestors Business Daily • 12/30/19
Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 12/25/19